Ipatasertib (AKT Inhibitor)

This compound and its uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Ipatasertib: An AKT inhibitor¹

Ipatasertib is an investigational, orally administered, ATP-competitive, selective AKT inhibitor. AKT is a key component of the PI3K/AKT pathway. This pathway is dysregulated in many malignancies, often through acquisition of activating mutations in AKT and phosphatidylinositol 3-kinase (PI3K), loss of the tumor suppressor phosphatase and tensin homolog (PTEN), or amplification of AKT and PI3K.^1,2

Some cancer treatments have led to the aberrant activation of the PI3K/AKT pathway, which resulted in the survival and proliferation of tumor cells.^1-4 In various preclinical models, PI3K/AKT/mammalian target of rapamycin (mTOR) signaling was shown to become activated following chemotherapy or antihormonal therapy.^2,3

Ipatasertib is designed to target and bind to the adenosine triphosphate (ATP)–binding pocket of the 3 activated isoforms of AKT, potentially inhibiting downstream signaling.¹ Ipatasertib is being investigated in combination with various treatment modalities (eg, antihormonal therapy, chemotherapy).^1,3

1. Ipatasertib is an oral, investigational small molecule currently being studied for its potential to inhibit all 3 isoforms of AKT.^1,5 Aberrant AKT signaling is associated with resistance to apoptosis and increased cell growth, proliferation, and metabolism.^1,2,4

2. Ipatasertib is designed to bind to the ATP-binding pocket of the 3 isoforms of AKT. By inhibiting AKT serine-threonine kinase activity, ipatasertib may inhibit tumor growth and proliferation through mTOR, as well as activate apoptotic signaling.^1-6

3. Preclinical data have shown that ipatasertib induced tumor growth delay or regression in AKT-activated tumor cells and xenograft models.¹ Ipatasertib continues to be investigated in ongoing clinical studies.

FOXO=Forkhead box O; GSK3=glycogen synthase kinase 3; mTORC=mammalian target of rapamycin complex; PDK1=phosphoinositide-dependent kinase-1; PI4,5P2=phosphatidylinositol 4,5-bisphosphate; PIP3=phosphatidylinositol 3,4,5-trisphosphate; RTK=receptor tyrosine kinase.

Ipatasertib proposed MOA

Watch how ipatasertib inhibits hyperactive PI3K/AKT pathway in cancer.